Phase III Study of Daratumumab/rHuPH20 NSC- 810307 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma MM Using Minimal Residual Disease to Direct Therapy Duration DRAMMATIC Study
A Multicentre, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of GSK2857916, Bortezomib, and Dexamethasone Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone in Participants with Relapsed/Refractory Multiple Myeloma
A Phase III, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide CC-92480, Bortezomib And Dexamethasone MEZIVd Versus Pomalidomide, Bortezomib And Dexamethasone PVd In Subjects With Relapsed Or Refractory Multiple Myeloma RRMM: SUCCESSOR-1
Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody
Phase I BCMA CAR T Trial in Relapsed or Refractory Multiple Myeloma Using our Next Generation of Investigational CAR-T Product Generated by a Unique Manufacturing Platform NEX-T
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma RRMM Who Have Normal and Varying Degrees of Impaired Renal Function DREAMM 12
Open-Label, Multicenter, Phase I Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed / Refractory Multiple Myeloma MM Followed by a Phase II Assessment of Response and Safety PRIME